GE Healthcare Life Sciences to Create New US Headquarters
News Aug 20, 2014
GE Healthcare Life Sciences announced today that it will open a new 160,000 square-foot facility in Marlborough, Massachusetts, as the new headquarters for its US operations. A $21M investment in the long-term future of this key GE Healthcare growth business, it will establish a new site for more than 500 GE Healthcare Life Sciences employees, including the creation of more than 220 new jobs in the US's leading life sciences and biotechnology cluster. Recruitment has begun with the site scheduled to open in Spring 2015, offering a dynamic working environment and career opportunities with a global leader in technology, science and business innovation.
“Our new facility in Massachusetts will position us for continued innovation and competition in such a fast-paced, innovative industry,” said Kieran Murphy, President and CEO of GE Healthcare Life Sciences. “We will be close to industry-leading talent, customers, and world-class academic and medical institutions across all the industry sectors we serve, from biotech and pharma, to diagnostics and medical devices.”
“Today, Massachusetts’ life sciences sectors are the fastest-growing sectors of our economy. We look forward to welcoming the U.S. life sciences headquarters of GE Healthcare and are pleased that the company will create a substantial number of new, STEM-related job opportunities in central Massachusetts,” said Governor Deval Patrick.
This investment will transform a currently unoccupied space into state-of-the-art labs, customer application facilities, and office space to complement GE Healthcare Life Sciences’ existing manufacturing capability in Westborough, Mass. The facility will consolidate GE Healthcare Life Sciences’ US East Coast presence, bringing together a critical mass of talent and expertise-dedicated collaboration, innovation and leadership in the industry. When fully operational, the new facility will bring more than 220 highly qualified new job opportunities to the area, including highly skilled positions such as lab technicians, biologists, medical doctors, process engineers, and customer service representatives.
GE Healthcare Life Sciences’ $4B business has more than 11,500 employees in over 100 countries, with the mission of enabling a new era of molecular and precision medicine. By providing customers with tools, insight and knowledge, GE Healthcare helps them accelerate the journey from biological understanding to clinical therapy. The new US headquarters will house employees from across the Life Sciences business, including its research, bioprocessing, medical imaging, in vitro diagnostics and services segments.
“Marlborough continues to be a center for innovation. This GE Healthcare Life Sciences investment, adding more than 220 new jobs with an exciting biotechnology leader, is proof that innovation is thriving outside Route 128, and of Marlborough’s ability to build the necessary infrastructure to attract top-tier, global life sciences companies,” said Mayor Arthur Vigeant.
“MassBIO continues to be engaged in policy, economic development and STEM education to foster the world’s leading biotech cluster. We are excited to continue work with industry leaders like GE Healthcare Life Sciences to promote innovation in the Greater Marlborough area,” said Robert Coughlin, President, MassBIO.
GE Healthcare Life Sciences has been actively supporting the development of new therapies for more than 60 years, with innovative technologies, services and solutions that enable the research, development, manufacture and use of the next generation of therapies. With technologies along the entire drug development, production and clinical continuum, GE helps scientists and physicians answer critical questions at every stage, from early research to patient diagnosis in the clinic.
Birch pollen allergic rhinitis is the most common chronic disorder in the Northern part of the globe, and it attributes to significant morbidity and economic burden. According to a new study, pollen allergen immunotherapy has favorable effects on the molecular events and microbiome profile in the nasal membrane.READ MORE